GSK PLC SAN CARLOS - Elegen, an innovation leader in DNA manufacturing, today announced a collaboration and licensing agreement with GSK (LSE/NYSE: GSK) to enable its use of Elegen's proprietary cell-free DNA manufacturing in GSK's vaccine and drug development.
The terms of the agreement include upfront fees and commitments to purchase ENFINIA DNA from Elegen to support GSK's drug and vaccine development, including RNA vaccines. Elegen is also eligible to receive both short-term milestone payments related to the development of new product features and a potential equity investment in Elegen by GSK.
Commercially launched in March last year, ENFINIA DNA offers high complexity, clonal quality, NGS (next generation sequencing) verified linear DNA of up to 7 kb in just seven business days. Unlike conventional mRNA synthesis from linearized plasmid DNA, Elegen's DNA is produced completely cell-free, with the potential to enable a seamless transition from discovery to clinical scale-up following GMP. This technology can save a lot of time and considerable resources devoted iteratively to cloning, linearization and purification of plasmid DNA, as well as generating master cell banks. Elegen's innovation in cell-free DNA manufacturing technology represents a major advance that could drive the next generation of gene, cellular and mRNA therapies.
This collaboration follows the 'Early Access Program' launched by Elegen in May last year, which offered DNA of greater length and complexity to select customers. 'Over the past year, dozens of customers, including several top 10 biopharmaceuticals, have validated the unprecedented speed, length, precision and complexity of our cell-free DNA manufacturing technology,' explains
About Elegen
Elegen brings unique insights and technical innovation to create high-quality synthetic DNA faster, catalyzing the next revolution in life sciences. The company is led by seasoned leaders with decades of experience developing novel and scalable approaches in molecular biology, chemistry and microfluidics. Elegen uses a patented microfluidic method to produce longer, higher quality DNA in less time for the agricultural, chemical, healthcare and pharmaceutical industries. Founded in 2017, Elegen is a privately held company based in the
The statement in the original language is the official and authorized version of it. This translation is only a means of assistance and must be compared with the text in the original language, which is the only version of the text that will have legal validity.
Contact:
Email: randy.dyer@elegenbio.com
Tel: (650) 787-0408
(C) 2024 Electronic News Publishing, source
